Serious adverse events/death: long‐term outcomes ‐ not reported · rehabilitation (long‐term outcomes)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse serious events (any) (number of participants) · patients with opioid dependence
It is very uncertain whether supervised dosing with a long‐acting medication changes adverse serious events (any) (number of participants) compared with unsupervised consumption (very low certainty).
1 finding from 1 review
Serious adverse events · children with acute asthma
1 finding from 1 review
Number of participants experiencing any serious adverse events · stable COPD
Long‐acting muscarinic antagonist (LAMA) plus long‐acting… showed no clear difference in serious adverse events (number of people experiencing ≥ 1 SAEs) compared with LABA plus inhaled corticosteroid (ICS) (high certainty).
1 finding from 1 review
Adverse events · participants with long‐term antidepressants for depressive disorders
1 finding from 1 review
Adverse events · participants with depressive or anxiety disorders
It is very uncertain whether abrupt discontinuation changes adverse events compared with continuation of long‐term antidepressants (very low certainty).
1 finding from 1 review
Adverse events · any physician, and any patient treated for chronic diseases with long‐term medication use
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term adverse events · women with breast cancer and one to three positive lymph nodes
1 finding from 1 review
Serious adverse events at up to 5‐year · 9‐ to 14‐year‐old females and males
It is very uncertain whether two doses of HPV vaccine with longer interval changes serious adverse events at up to 5‐year compared with two doses of HPV vaccine with shorter interval (very low certainty).
1 finding from 1 review
Overall local/injection site adverse events · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term serious adverse events · patients with rheumatoid arthritis
1 finding from 1 review
Intervention not reported
Serious adverse events at longest · participants with gallstone disease (cholesterol, pigment, or mixed)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events at longest · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention showed no clear difference in serious adverse events at longest (low certainty).
1 finding from 1 review
Adverse events: all cause – long term · people with schizophrenia or other serious mental illness
It is very uncertain whether peer support plus standard care changes adverse events: all cause – long term compared with standard care (very low certainty).
1 finding from 1 review
Serious adverse events at longest · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher serious adverse events (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review
Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension
1 finding from 1 review